Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...

アクシスコンサルティングは22日、東京理科大学インベストメント・マネジメントと連携し、東京都のスタートアップ支援事業「TOKYO SUTEAM」で採択された先端科学分野特化のアクセラレーションプログラム「TUSIDE起業加速プログラム（TUSIDE EAP）」を実施すると発表した。

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Employers can support their team members by providing access to employee assistance programs (EAPs). This resource helps ...

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

The prestigious HR Asia awards are based on employee feedback and an organisational audit to assess culture, engagement, and ...

Winter weather is driving up energy costs, but local programs and assistance funds can help families stay warm and keep the lights on.

The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...

NPC is an ultra-rare, relentlessly progressive, genetic disorder that leads to premature mortality. MIPLYFFA, used in conjunction with miglustat, is the only treatment shown to halt disease ...

認証・表彰 フェデックス（米国）のマレーシア法人であるフェデックス・マレーシア（クアラルンプール）はこのほど、HRアジア誌が選出する「アジアで最も働きがいのある企業2025」に5年連続で選ばれたと発表した。あわせて、従業員への配慮を評価する「Most ...